Dietary supplementation with Bifidobacterium lactis NCC2818 from weaning reduces local immunoglobulin production in lymphoid associated tissues but increases systemic antibodies in healthy neonates.
It is clear that the intestinal microbiota provides the first line of defence against pathogenic organisms (1, 2) . However, it is becoming more apparent that it also exerts a major influence over host homeostasis in healthy humans and animals (3 -6) . The microbiota can be altered by factors such as diet (7) and environment (4 -6) , but in adults, the mature microbiota tends to re-establish itself once the external influence is removed (8) .
More long-term alterations may be generated during early life, when this intestinal ecosystem is still fluctuating (9) and highly susceptible to change (10, 11) . The process of microbial colonisation and succession in the intestine is a major factor in driving maturation of the immune system (12 -16) , and the composition of the microbiota can affect the function of the immune system in neonates and adults (17) . Some specific modifications of the microbiota have been correlated with disease (10, 18, 19) , and clinical trials have suggested that strain-specific probiotic therapy can confer a health benefit for specific disease situations (20 -24) . The process of weaning is associated with a major shift in the gut microbial community in both humans (25) and other mammals (26) , and therefore may present a target for beneficial manipulation of the microbiota. Intervention with probiotics during weaning may have a more pronounced impact on the subsequent function of the immune system than administration of probiotics to adults.
Assessing the likely value of a probiotic in a specific clinical situation requires either direct measurement of health benefit as part of a clinical trial, or an understanding of the mechanism of action of the probiotic. The size and robustness of the evidence base will allow rational selection of specific probiotic strains and the clinical situations in which trials are likely to have positive outcomes. However, the extent to which mechanistic studies can be carried out in human subjects is limited. Neonates of altricial species such as rodents are not easily manipulated: in contrast, the omnivorous pig is not only similar to humans in terms of anatomical, physiological, immune and metabolic characteristics (27 -31) but, in addition, their precocial development makes them appropriate candidates for manipulation around weaning. Effects of early-life environment on microbial colonisation have been identified in young piglets (4) , and intra-individual stability and inter-individual variability of the microbiota are more similar between humans and pigs than between humans and mice (32) . Further, full genome studies have demonstrated less differences between humans and pigs than between humans and rodents (33, 34) . These factors suggest that piglets are a valuable intermediate between highly reductionist, mechanistic studies in mice, and human epidemiological studies and clinical trials, especially with regard to weaning and nutritional intervention. Here we use a healthy piglet weaning model to identify the effects of intervention with the human probiotic Bifidobacterium lactis at weaning on immunological development and function, and question how well generally accepted proxy measures of health truly reflect the physiological status of an individual.
Materials and methods

Animals
Animal housing and experimental procedures were all performed according to local ethical guidelines: all experiments were performed under a UK Home Office License and were approved by the local ethical review group. A total of seven outbred sows were artificially inseminated using semen from a single boar (supplied by Hermitage-Seaborough Limited). Sows were transported to the Department of Clinical Veterinary Science 6 weeks before parturition and fed on a wheat-based diet (BOCM Pauls Limited). At 3 weeks of age, piglets were weaned and litter-matched into six groups (Table 1) , each group being housed in a separate room, on straw, in standard large animal facilities.
At this point, three groups received the B. animalis subsp. lactis (CNCM I-3446) probiotic diet supplementation in the form of spray-dried culture mixed into the formula at a concentration of 4·2 £ 10 6 colony-forming units/ml (approximately 2 £ 10 9 colony-forming units/kg metabolic weight per d). The required quantity of feed supplemented with fresh probiotics was fed twice per d to the appropriate groups (A -C) until the experiment concluded when the pigs were 11 weeks old. The remaining groups (D-E) did not receive the probiotic supplement. The probiotic-fed and control animals were in different suites separated by a biosecurity barrier. Of the piglets receiving probiotics, two groups were weaned onto a soyabased diet and one onto an egg-based diet ( Table 2 ). All diets were supplemented with appropriate levels of vitamins and minerals and were manufactured to order by Volac (Parnutt) Foods Limited. The weaning diets were designed such that the only differences were that each contained 21 % of the stated protein.
One of the two groups that weaned onto the soya-based diet also received an intraperitoneal injection of 2 mg soluble ovalbumin from chicken egg-white (systemic exposure; Sigma) and 2 mg Quil A adjuvant (Brenntag Biosector A/S) in 2 ml PBS to investigate the immune response against a systemically administered novel protein. The treatment of these three probiotic-supplemented groups (A -C) was replicated in the probiotic-free control groups D to F. From 7 weeks of age, all six groups were fed a fishmeal-based diet, free of egg and soya, either with or without probiotic as appropriate. The fishmeal diet was used to ensure that the serum antibody response was to the injected egg protein and not to the dietary egg protein. The egg-and soya-based diets were designed to meet the nutritional requirements of piglets between 3 and 7 weeks old, whereas the fishmeal-based diet was designed for piglets between 7 and 11 weeks old. For this reason, the fishmeal-based diet cannot be compared with the egg-and soya-based diets. The composition of the different diets is shown in Table 2 . At 9 weeks old, all piglets received an intraperitoneal injection of 2 mg ovalbumin and 2 mg Quil A adjuvant in 2 ml PBS. All piglets were bled by venepuncture at 3, 4, 5, 7 and 9 weeks old for collection of serum. At 11 weeks old, piglets 
i.p., Intraperitoneally; OVA, ovalbumin. * Forty-two (six piglets from seven litters) piglets were litter-matched into six treatment groups; three groups received the B. lactis NCC2818 intervention at weaning at 3 weeks of age.
were sedated with azaperone and killed with an overdose of barbiturate. At post-mortem, heart blood and tissues were recovered.
Tissue culture
At killing, 4 cm 2 samples of intestinal mucosa (proximal and distal jejunum, excluding Peyer's patches (PP), distinct jejunal PP, caecum and descending colon), and 1 cm 3 of spleen and mesenteric lymph node (MLN) were collected and placed in cold sterile medium. Organ fragment culture was carried out as described in detail by Logan et al. (35) . Briefly, the samples were vigorously washed three times in Ca 2þ and Mg 2þ -free Dulbecco's PBS (Sigma) containing 0·5 mM-EDTA (Sigma), 1 M-HEPES (Invitrogen) and 50 mg gentamycin/ml (Gibco), followed by three further washes in Ca 2þ and Mg 2þ -free Dulbecco's PBS containing 1 % HEPES and 50 mg gentamycin/ml before being placed in Roswell Park Memorial Institute-1640 medium (Sigma) containing 10 % fetal calf serum (PAA), 200 mM-L-glutamine (Invitrogen), 10 units penicillin/ml and 10 mg streptomycin/ml (Invitrogen) and 50 mg gentamycin/ml (complete medium). Intestinal tissues were cut into fragments approximately 3 mm 2 , while spleen and MLN were cut into 2 mm cubes, and one fragment of tissue was placed in each of six individual wells of a twenty-four-well culture plate (Corning, Inc.) containing 1 ml of complete medium. Cultures were incubated at 378C, 5 % CO 2 , 100 % humidity for 96 h, after which they were frozen at 2 208C. The plates were defrosted and the spent medium from each of the six duplicate wells for each sample was pooled and refrozen for analysis of Ig content.
Immunoglobulin assays
Catching ELISA was carried out to determine total IgG 1 , IgG 2 , IgA and IgM in spent medium from organ fragment cultures and IgA in serum. Briefly, ninety-six well microplates were coated with either affinity-purified goat anti-pig IgG (H þ L), goat anti-pig IgA or goat anti-pig IgM (Bethyl Laboratories). Serial dilutions of serum samples and reference standard were added to coated plates and incubated for 2 h at room temperature. Bound Ig were detected using isotype-specific monoclonal antibodies (anti-pig IgA K61.1B4, anti-pig IgM K52.1C3, anti-pig IgG 1 K139.3C8 and anti-pig IgG 2 K68.1G2; all from Serotec) followed by horseradish peroxidase-conjugated goat anti-mouse IgG 1 . Concentrations of Ig subclasses were determined by interpolation of samples onto the reference standards.
Antigen-specific immunoglobulin assays
Serum samples were analysed for anti-ovalbumin IgG 1 and IgG 2 antibodies by ELISA as described in detail by Bailey et al. (36) . Briefly, ninety-six-well microplates were coated with ovalbumin from chicken egg-white (Sigma) before non-specific binding sites were blocked with 2 % bovine serum albumin (Sigma) in PBS -Tween 20. After washing, serial dilutions of serum samples and reference standard were added to the plates. Reference standard was porcine serum obtained following hyperimmunisation with ovalbumin. Bound anti-soya IgG 1 and IgG 2 antibodies were detected using isotype-specific monoclonal antibodies followed by HRPconjugated goat anti-mouse as mentioned previously, and relative concentrations of antibody were determined by interpolation of samples onto the reference standards. In order to compare changes in serum antibody generated by weaning and by the injection of novel proteins in outbred animals, in which the starting levels differ, results are expressed as the ratio of antibody after manipulation to that before manipulation (fold change in antibody).
Immunohistology
Sample collection. MLN and caecum tissue was removed shortly after death from each of the experimental piglets. Tissues were embedded in OCT (Tissue TEK; BDH), snap-frozen in isopentane and pre-cooled to approximately 2708C in the vapour phase of liquid N 2 . Samples were stored at 2 808C until sectioning. Serial 5 mm sections of these tissues were cut using a Model OTF cryotome (Bright Instrument Company Limited). Sections were air-dried for 24 h and then fixed by immersion in acetone for 15 min. Slides were allowed to dry before storage at 2 808C.
Fluorescence immunohistology. For two-colour fluorescence immunohistology, mouse anti-pig monoclonal antibodies (IgA and IgM, as for ELISA) were used to identify free and cell-bound IgA-and IgM-positive cells and B-lymphocytes (anti-CD21, clone IAH CC55). The conjugated secondary reagents used were as follows: goat anti-mouse IgG 1 conjugated to fluorescein isothiocyanate (FITC) (Southern Biotechnology, AMS Biotechnology) and goat anti-mouse IgG 2b conjugated to tetramethyl rhodamine isothiocyanate (TRITC) (Southern Biotechnology). Tissue staining, image capture and automated image analyses were carried out as described by Inman et al. (37) with the exception that fracture crystallography (Fc) receptor blocking was achieved using 10 % goat serum in PBS.
Histochemistry
Small-intestinal samples were obtained as described in the immunohistology section and processed the same up to and including the acetone fixation step. Fixed slides were stained for mast cells using 2·5 % toluidine blue O solution (SigmaAldrich) for 15 s followed by dehydration through increasing concentrations of alcohol culminating in a histoclear w (National Diagnostics) wash and mounted in distyrene plasticiser xytene (DPX) mounting medium (Fisher). Image capture was carried out using a Colour Coolview camera and ImagePro Plus software (Photonic Science). Thereafter, ten fields of view were obtained from each piglet and ImageJ software (National Institutes of Health) was used to allow quantification of mast cells per cm 2 tissue.
Statistical analysis
Statistical analysis was carried out using SPSS statistics (SPSS, Inc.). Univariate linear regression was carried out using piglet as the experimental unit and litter, tissue and probiotic treatment as variables. Individual differences between the treatment groups were determined by least significant differences as in our previous experiments (3) .
Results
Local immunoglobulins
Bifidobacterium lactis NCC2818 supplementation caused a reduction in local immunoglobulin production in lymphoidassociated organ fragment cultures. Total IgG 1 , IgG 2 , IgA and IgM were quantified in organ fragment culture medium from all animals. There were highly significant differences in the amounts of the four isotypes produced between tissues (P,0·0001), spleen producing less IgA (2 0·16 (SEM 0·04) log 10 mg/ml) than mucosal tissues in the control animals (mean range 2 0·5-1·16 log 10 mg/ml). Highly significant effects of probiotic intervention were observed for IgA (P,0·0005; Fig. 1(a) and (b)) and IgM (P,0·009; Fig. 1(c) and (d) ), but not for IgG 1 or IgG 2 (data not shown). IgA and IgM were lower in the probiotic supplemented animals than in the unsupplemented animals (for IgA from MLN, 2 0·56 (SEM 0·09) and 0·34 (SEM 0·05) log 10 mg/ml, respectively; from proximal jejunum, 0·75 (SEM 0·03) and 0·86 (SEM 0·01) log 10 mg/ml; from jejunal PP, 0·02 (SEM 0·09) and 0·80 (SEM 0·09) log 10 mg/ml; from caecum, 0·74 (SEM 0·06) and 1·17 (SEM 0·05) log 10 mg/ml; for IgM from MLN, 0·38 (SEM 0·08) and 0·72 (SEM 0·03) log 10 mg/ml, respectively; from caecum, 0·13 (SEM 0·18) and 0·85 (SEM 0·03) log 10 mg/ml; from colon, 0·60 (SEM 0·04) and 0·81 (SEM 0·03)) log 10 mg/ml). There was also a significant interaction between probiotic treatment and tissue (P,0·0001 for both classes), such that this effect was more marked for some tissues than others. Specifically, probiotic intervention appeared to have the most marked effect on IgA production by the organised tissues of MLN and jejunal PP ( Fig. 1(a) ), and to a lesser extent by the diffuse lymphoid tissue present in caecal mucosa ( Fig. 1(b) ). Although supplementation also resulted in significantly decreased IgA production by tissue from the proximal small intestine, the effect was much smaller. IgA production in the spleen, distal small intestine and colon showed no difference between the probiotic supplemented and non-supplemented animals (from spleen, 20·25 (SEM 0·04) and 20·16 (SEM 0·04) log 10 mg/ml, respectively; from distal jejunum, 0·46 (SEM 0·03) and 0·44 (SEM 0·07) log 10 mg/ml; from colon, 1·16 (SEM 0·02) and 1·06 (SEM 0·05) log 10 mg/ml). There was also no difference as a result of dietary supplementation in spleen or smallintestinal IgM (for spleen, 0·62 (SEM 0·09) and 2 0·79 (SEM 0·06) log 10 mg/ml, respectively; from proximal jejunum, 0·36 (SEM 0·07) and 0·36 (SEM 0·07) log 10 mg/ml; for distal jejunum, 0·27 (SEM 0·06) and 0·40 (SEM 0·05) log 10 mg/ml; for discrete jejunal PP, 0·75 (SEM 0·05) and 0·35 (SEM 0·05) log 10 mg/ml). It should be noted that IgA in serum taken at time points throughout the experiment remained unaltered by the supplementation with B. lactis NCC2818 (P.0·05). Local IgA and IgM proteins were reduced in caecal tissue, mesenteric lymph node-associated B-cells and B-cell follicles following probiotic intervention. In order to examine the mechanisms by which probiotic administration reduced Ig secretion in organ fragment cultures, levels of IgA, IgM and CD21 were examined in MLN (Figs. 2 and 3 ) and caecum (Fig. 4) samples from groups B and E (soya diet, supplemented with the probiotic and control, respectively). These tissues and groups were chosen as they had previously produced the most consistent differences in organ fragment cultures. Consistent with the organ fragment culture data, there was reduced expression of IgA ( Fig. 2(a) and (d) ), IgM ( Fig. 2(d) ) and also Fig. 2(c) ), within B-cell follicles in the MLN of the B. lactis NCC2818-treated animals compared with the control group (P,0·0001). There was no effect of intervention with B. lactis NCC2818 on the total number of MLN follicles (P.0·05; Fig. 3(a) ), but the number of IgM-specific follicles (Fig. 3(c) ) and extrafollicular IgM-producing B-cells (Fig. 3(b) ) was reduced in the animals receiving the intervention (P,0·0001). In contrast, no change was seen in the number of extrafollicular IgA-positive cells (Fig. 3(b) , P.0·05), whereas the number of IgA-specific follicles was actually significantly increased ( Fig. 3(c) ) in animals fed with B. lactis NCC2818 when compared with the controls (P,0·0001). Reductions in the expression of IgA (Fig. 4(a) and (c)) and IgM (Fig. 4(b) and (d)) in situ in the caecum were also apparent (Fig. 4) , both in the subepithelial lamina propria (associated with production) and in the caecal crypt epithelium (associated with transport) (Fig. 4 
CD21 (
(c) and (d)).
A reduction in lymphoid-associated IgA and IgM production was associated with increased mast cell numbers in the intestinal mucosa
In contrast to the decreases observed in IgA and IgM in the supplemented animals, there were significantly greater numbers of mast cells in the small intestine (P,0·001) of animals which received B. lactis NCC2818 (n 7) when compared with the control (Fig. 5 ).
Systemic antibody
Primary systemic response to novel fed protein at weaning was increased following Bifidobacterium lactis NCC2818 administration. At weaning, there was a significant increase in IgG 2 anti-soya antibody in animals which received a soya diet with probiotic supplementation when compared with both the animals fed soya without probiotic and the egg-fed animals (P¼ 0·021; Fig. 6(a) ). The supplemented animals also mounted a significantly greater IgG 1 antibody response to soya compared with the egg-fed controls (P¼0·03), and a greater response than the unsupplemented animals fed soya, although this was not significant (Fig. 6(b) ). Primary and secondary responses to injected antigens were increased following probiotic intervention at weaning. Fig. 7(a) and (b) shows the increase in serum IgG 1 and IgG 2 antibody, respectively, during the primary and secondary responses to systemically injected antigens (with the adjuvant). During the primary response (3 -5 weeks old), there were trends towards an increased serum IgG 1 and IgG 2 anti-ovalbumin response in the B. lactis NCC2818-fed animals (n 7) compared with the control group. During the secondary response (9 -11 weeks old), there was a significantly greater response in both isotypes in the supplemented group (IgG 1 , P¼ 0·05 and IgG 2 , P¼0·02).
Discussion
The common definition of a probiotic (given by the WHO in 2001) is 'a live microorganism that when administered in adequate amounts confers a health benefit on the host'. Thus, the definitive outcome measure necessary when testing novel strains for probiotic activity is health: in normal or diseased humans or animals, this may be measured, for example, by susceptibility to disease. However, understanding the mechanisms by which probiotics function requires detailed measurement of a wider range of immunological and physiological parameters, which may then also be used as proxy measures of health. The strain of B. lactis NCC2818 used in the present experiments has been identified as having probiotic activity, as defined above, in human subjects and in rodent models. These benefits include reducing pathogen load and prevention or reduction of antibiotic-associated diarrhoea (38, 39) .
However, the effects of probiotics, including B. lactis NCC2818, on immune development at weaning, a time when the resident microbiota is changing rapidly, are largely unknown. The immunological measures reported here, then, relate to the mechanisms of action of the probiotic strain and to the identification of proxy measures of the probiotic effect. The results presented clearly demonstrate that administration of B. lactis to piglets at weaning had marked effects on the structure and function of the mucosal immune system. In that respect, the present results are comparable with mechanistic experiments in rodents and with the data from human clinical trials. In our system, intervention with B. lactis NCC2818 resulted in reduced IgA in mucosal-associated lymphoid tissues (associated with a reduction in plasma cell numbers by immunohistology). In contrast, preterm infants, which received B. lactis NCC2818 for 3 weeks following birth, showed a 2-fold increase in faecal IgA levels from 2 weeks onwards (40) , and IgA production by MLN and PP cells from adult mice was increased when cultured in the presence of Bifidobacterium bifidum (41) . In a mouse study, IgA in the intestinal fluids of the supplemented animals was also higher than that in the controls. In these and previous studies, elevated secretory IgA has been presumed to be a mechanism or a proxy measure for a beneficial effect of probiotics (42) , presumably by increasing the potential for neutralisation of allergens or pathogen, thus preventing or reducing disease. The disparity between the present results and those reported in human subjects and rodents may be more apparent than real. Where intervention has resulted in increased IgA levels in vivo, it should be noted that faecal IgA levels and total intestinal washes, as normally carried out in these species, may be more reflective of jejunal and/or colonic mucosal IgA levels, where there was no effect of supplementation in pigs of the present study, rather than the MLN, PP and caecum, where there was an effect. In addition, studies in human subjects have frequently involved compromised individuals (40) , whereas the present study used normal, outbred healthy piglets. While an increase in faecal IgA has been correlated with protection, the same correlation has not been established for local tissue IgA. Interestingly, an increase in intestinal IgA can be linked to various disease states in humans (43 -45) , and a local increase of IgA in a healthy individual can also be an indication of the loss of barrier function. We thus suggest that the present observation that probiotic supplementation decreased, rather than increased, local IgA production in intestinal tissue reflects a reinforcement of the intestinal barrier (preventing exposure to luminal antigens) rather than a suppression of mucosal immunity, and a breakdown in barrier function is often associated with disease. It also suggests that while elevated IgA in the faeces is accepted as a proxy measure for health, the same interpretation cannot necessarily be applied to local IgA production in tissues. Similarly, although elevated numbers of mast cells have been associated with allergic sensitisation (46) , the increases in mast cell numbers seen here were within the normal ranges previously reported in young piglets (47, 48) , and are in line with physiological numbers in adult pigs (49) and were not comparable with those seen in disease states (50, 51) . An increase in mast cell numbers within the normal physiological range may be a consequence of increased recruitment to the intestinal mucosa, decreased mast cell exit or the inhibition of mast cell degranulation. Previous studies have suggested that mast cell degranulation contributes to impaired barrier function after weaning in young piglets, and several probiotic species have been shown to reduce IgE-mediated degranulation in an RBL-2H3 cell line (39, 51) . A reduction in antigen-induced mast cell degranulation may also occur as a consequence of elevated IgG antibody responses to fed and injected antigens in probiotic supplemented animals: elevated serum IgG antibody responses to food proteins have been associated with decreased susceptibility to IgE-mediated allergic disease in human subjects and to post-weaning diarrhoea in pigs (52, 53) . Further, since active, primary responses to intestinal antigens are largely mediated through PP (54) while tolerance is mediated by the transfer of antigens from the intestinal mucosa to the MLN (55) , stronger responses to fed antigens in supplemented piglets may also indicate reduced uptake across the intestinal epithelium compared with PP. The present results strongly suggest caution in interpreting specific measures of the immune system (in this case, IgA production, mast cell numbers and antibody to food proteins) as linear, proxy measures for the health benefit of probiotic supplementation in the diet without taking the specific animal model and, more importantly, the specific intervention window into account.
Mechanistically, the present results are largely consistent with B. lactis NCC2818 intervention, increasing barrier function between the lumen and the intestinal lamina propria. Specifically, a reduction in IgA production in organ fragment cultures is entirely consistent with a reduced exposure of the mucosal immune system to antigens derived from the intestinal lumen. Previously, certain probiotics, including bifidobacteria, have been shown to enhance the barrier function of human intestinal epithelial cells in vitro (56) , but not in vivo, in part by the stabilisation of tight cell junctions (57) . B. bifidum, for example, was demonstrated to increase barrier integrity in a rat model of neonatal necrotising enterocolitis (58) . In conclusion, the present results demonstrate clear effects of probiotic supplementation in the weaning diets of conventionally reared animals which do not have any diseases or unusual pathology. Mechanistically, these effects are consistent with increased barrier function. However, the results also strongly suggest that while measures of the effect of probiotic supplementation on the immune system are of value in developing an understanding of the mechanism of action, we may need to interpret with caution. While studies of health benefits are appropriately conducted in human subjects, mechanistic studies require tractable animal models from which sufficient tissue samples can be easily recovered. Such mechanistic studies should, perhaps, be carried out in several mammalian species in order to establish generally applicable principles for predicting the activities of probiotic strains. 
